Supplementary data.docx (1.19 MB)
Download fileSupplementary data: Methods to evaluate the impact of SARS-CoV-2 nucleocapsid mutations on antigen detection by rapid diagnostic tests
figure
posted on 2022-08-25, 07:58 authored by Bryan C Tieman, Stephen Kovacs, Mary A. Rodgers, Aurash Mohaimani, Svetoslava Gregory, David Christensen, Jeffrey A. Moore, Lici A. Schurig-Briccio, James R. Hartnett, Alak Kanti Kar, Aaron Leeman, Angela C. Palmer, Lauren Rogers, Brian Dragoo, Steven Muszynski, Deborah Noblesmith, Samantha Gardner, Abigail Snipe-Bushey, Anna Kill, Xinxin Luo, Sneha Cherukuri, Tracey Rae, Christopher C Marohnic, Gavin A. Cloherty, A. Scott Muerhoff, Philip M Hemken
Supplemental Table S1. SARS-CoV-2 Variants Included in the Analysis
Supplemental Table S2. Anti-nucleocapsid Antibodies Used in Each Assay
Supplemental Figure S1. Representative immunoblots of all recombinant SARS-CoV-2 nucleocapsid antigens (rAg; see Table 1) with anti-nucleocapsid antibodies used in the Panbio assay (Ab1, Ab2) and BinaxNOW assay (Ab3, Ab4).
Supplemental Figure S2. Normalized Sensorgrams of Ab1 Binding Captured SARS-CoV-2 Nucleocapsids.
Supplemental Figure S3. Normalized Sensorgrams of Ab2 Binding Captured SARS-CoV-2 Nucleocapsids
